These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 15925069

  • 1. Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?
    Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H.
    Eur Urol; 2005 Jun; 47(6):756-60. PubMed ID: 15925069
    [Abstract] [Full Text] [Related]

  • 2. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA.
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [Abstract] [Full Text] [Related]

  • 3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group.
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [Abstract] [Full Text] [Related]

  • 4. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    Boorjian SA, Bianco FJ, Scardino PT, Eastham JA.
    BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
    [Abstract] [Full Text] [Related]

  • 5. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Oct; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 6. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 7. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 8. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
    Phillips JJ, Hall MC, Lee WR, Clark PE.
    Urol Oncol; 2007 Feb; 25(3):196-200. PubMed ID: 17483015
    [Abstract] [Full Text] [Related]

  • 9. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
    Patel DA, Presti JC, McNeal JE, Gill H, Brooks JD, King CR.
    J Clin Oncol; 2005 Sep 01; 23(25):6157-62. PubMed ID: 16135482
    [Abstract] [Full Text] [Related]

  • 10. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H.
    J Urol; 2002 Mar 01; 167(3):1306-9. PubMed ID: 11832719
    [Abstract] [Full Text] [Related]

  • 11. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC.
    J Urol; 2004 Apr 01; 171(4):1492-9. PubMed ID: 15017206
    [Abstract] [Full Text] [Related]

  • 12. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Mol Urol; 2000 Apr 01; 4(3):171-5;discussion 177. PubMed ID: 11062371
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [Abstract] [Full Text] [Related]

  • 14. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H.
    J Urol; 2000 Jul 15; 164(1):101-5. PubMed ID: 10840432
    [Abstract] [Full Text] [Related]

  • 15. Are positive surgical margins in radical prostatectomy specimens an independent prognostic marker?
    Saether T, Sørlien LT, Viset T, Lydersen S, Angelsen A.
    Scand J Urol Nephrol; 2008 Jul 15; 42(6):514-21. PubMed ID: 18752153
    [Abstract] [Full Text] [Related]

  • 16. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT.
    J Urol; 2005 Sep 15; 174(3):903-7. PubMed ID: 16093984
    [Abstract] [Full Text] [Related]

  • 17. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 15; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 18. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
    Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Terris MK, SEARCH Database Study Group.
    J Urol; 2006 Apr 15; 175(4):1298-302; discussion 1302-3. PubMed ID: 16515984
    [Abstract] [Full Text] [Related]

  • 19. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [Abstract] [Full Text] [Related]

  • 20. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW.
    Cancer; 2004 Dec 01; 101(11):2549-56. PubMed ID: 15470681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.